Navigation Links
assisTek's ePRO Biotech Clinical Trial Data Collection Saves Client $1.6 Million Over Paper Questionnaires
Date:10/27/2008

Five years ago, a large biotech company began collecting ePRO (electronic patient reported outcomes) data using .assisTek's proven tablet system in clinical trials around the world. Recently, assistek's financial team calculated the costs of using the assisTek system compared to what it would have cost if the client had used traditional paper questionnaires. The results showed that assisTek's ePRO data collection saved the client $1.6 million over paper questionnaires over 10 studies.

Scottsdale, AZ (PRWEB) October 27, 2008 -- Five years ago, a large biotech company began collecting ePRO (electronic patient reported outcomes) data using assisTek's proven tablet system in clinical trials around the world. Recently, assistek's financial team calculated the costs of using the assisTek system compared to what it would have cost if the client had used traditional paper questionnaires. The results showed that assisTek's ePRO data collection saved the client $1.6 million over paper questionnaires over 10 studies.

The results were significant and wide ranging. assisTek's ePRO tablets saved the customer money in 7 out of the 10 studies, with 1 study saving over $1,000,000 alone. In addition, the customer benefited from much more rapid access to significantly higher quality data than would be possible with paper-based questionnaires. The customer also enjoyed assisTek's industry leading online study management system, which provides real time management reports, which also would have not been possible with paper questionnaires.

"All of assisTek's ePRO data collection products deliver patient reported outcomes data in clinical trials that is consistently more than 99% complete," said Joy Hebert, Chief Operating Officer. "This means that clients can significantly reduce queries, and the significant time and labor traditionally required for resolving them. In addition, our unique system reduces workload by more 90%."

For more information about assisTek's ePRO systems or to schedule a free no-obligation demonstration, contact Reinet Marneweck at reinet.marneweck@assistek.com.

About .assisTek:
.assisTek is the global leader in ePRO systems and has revolutionized the process of collecting patient-reported outcomes in clinical trials by helping sites collect the data electronically and systematically through large 9 inch tablet touch-screens, iPhones, mobile PDAs, and on the web.
.assisTek's ePRO products are the most advanced in the industry. The .assisTek team has the deepest knowledge and experience in the industry having served more than 45,000 patients in more than 35 therapeutic areas at more than 4,500 sites across 5 continents.

.assisTek, formerly Assist Technologies, can be found on the web at assisTek.com.

# # #

Read the full story at http://www.prweb.com/releases/ePRO/clinical-trials/prweb1520734.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New Cost-Effective Anti-Fatigue Solution from MEGAComfort Now Available for Employees in Biotech and Research Industries
2. Prix Galien USA Recognizes Biotech, Pharmaceutical Industries for Innovative Medical Treatments
3. Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria
4. Veteran of the Beverage Industry, Ken Sadowsky, Joins Millennium Biotechnologies Board of Directors
5. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
6. UCLA and biotech company develop first blood test to measure key hormone that regulates iron
7. InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
8. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
9. The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health
10. China Kangtai Cactus Biotech Inc. Launches Cactus Cattle Feed and Cactus Fish Feed
11. Pulmo BioTech Inc. Announces Possibility of MRI Application for PulmoBind
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
assisTek's ePRO Biotech Clinical Trial Data Collection Saves Client $1.6 Million Over Paper Questionnaires 
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: